Skip to main content

Genotyping Assay Market Worth USD 31.9 Billion : Decreasing Prices Of DNA Sequencing

 Major Growth Boosters:

The major factors that are expected to be driving the genotyping assay market are technological advancements and the decreasing prices of DNA sequencing. The increasing incidence of genetic diseases and rising awareness of personalized medicine, growing importance of genotyping in drug development, and the increasing demand for bioinformatics solutions in data analysis are also expected to promote market growth in the coming years. The objective of the report is to define, describe, and forecast the genotyping assay market size based on product & service, technology, application, end user, and region.

What This Report Will Provide?

Genotyping platforms have several potential application areas such as pharmacogenomics, diagnostic research, personalized medicine, and forensics. Furthermore, this technology is also apt for a range of veterinary needs, food safety and quality, and environmental testing in remote areas and industrial settings. At present, human diagnostics and pharmacogenomics offer significant marker potential as these segments require rapid genotyping analysis on a large scale due to the need for better treatment options and high disease prevalence.

Expected Revenue Growth:

MarketsandMarkets forecasts the Genotyping Assay market to grow from USD 11.8 billion in 2018 to USD 31.9 billion by 2023, at a Compound Annual Growth Rate (OTC:CAGR) of 22.0% during the forecast period.



 Recent Developments

  • In May 2018, Agilent technologies opened a new logistics center in Texas to increase its capacity for house inventory and to fulfill the growing demand for NGS products from its genomics group.
  • In March 2018, Danaher Corporation acquired Integrated DNA Technologies Inc. (US). This acquisition strengthened Danaher’s Life Sciences platform. IDT will operate as a standalone operating company and brand within Danaher Corporation.
  • In January 2018, Thermo Fisher Scientific signed a partnership with Illumina (US) that enabled Illumina to sell the Ion AmpliSeq technology to researchers who conduct scientific studies using Illumina’s next-generation sequencing (NGS) platforms.
  • In January 2018, Illumina launched the iSeq 100 Sequencing System.
  • In January 2018, Thermo Fisher Scientific launched the Ion GeneStudio S5 Series Instrument.

Key Questions Addressed in The Report:

  • Where will all these developments take the industry in the long term?
  • What are the upcoming trends for the genotyping market?
  • Which segment provides the most opportunity for growth?
  • Who are the leading players operating in this market?
  • What are the opportunities for new market entrants?

Request Sample Report:   ttps://www.marketsandmarkets.com/requestsampleNew.asp?id=249958595 

Technological Advancements and Decreasing Prices of DNA Sequencing

Technical advancements have allowed for miniaturization, automation, and reduced overall costs, as well as operational flexibility and the incorporation of multi-parameter testing. All of these have greatly helped increase the applications and convenience of DNA sequencing, allowing physicians to focus on high-level decision-making such as identifying and prioritizing drug targets through various genotyping studies. This has directly boosted the uptake of PCR, sequencing, capillary electrophoresis, and microarray technologies in fields such as drug discovery and clinical research.

Regional Growth Analysis:

North America is expected to hold the largest market size in the global genotyping market during the forecast period, followed by the European region. The increasing adoption of technologically advanced genotyping products, the high healthcare expenditure, presence of advanced healthcare infrastructure, highly developed healthcare systems in the US and Canada, large number of genotyping-based R&D projects, and the presence of a large number of leading genotyping manufacturers in the region, along with an increasing demand from pharmaceutical companies for genotyping products and rising investments by government bodies, are responsible for the large share of the North American genotyping market.

Download PDF Brochure:     https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=249958595 

Labels:

Comments

Post a Comment

Popular posts from this blog

Inspection Machines Market To Reach USD 871 Million By 2025 - Growing Demand For Personalized Medicine

  What This Report Will Provide? This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies. Expected Revenue Growth: The  Inspection machines market  is projected to reach USD 871 million by 2025 from USD 671 million in 2020, at a CAGR of 5.4% during the forecast period. Major Growth Boosters: The growth of this market is majorly driven as companies are now increasingly adopting inspection systems throughout their production lines due to the growing concerns to the regulatory mandates introduced by the government and regulatory bodies in the healthcare industry to maintain compliance with Good Manufacturing Practices ( GMP ). Download PDF Brochure:    https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=81453085   CO...
Post a Comment
Read more

What are the growth opportunities offered by the Digital Therapeutic (DTx) Market in the next five years?

  The growth of the digital therapeutics market is primarily driven by factors such as government initiatives for preventive healthcare, technological advancements in mobile healthcare, a significant increase in venture capital investments, and the benefits of digital therapeutics, such as the ability to induce behavioral change (an important challenge in healthcare), user-friendliness, patient convenience, and improved drug compliance. The global  digital therapeutics market  is projected to reach USD 6.9 billion by 2025 from USD 2.1 billion in 2020, at a CAGR of 26.7% during the forecast period (2020–2025). On the other hand, a lack of awareness and access to digital therapeutics programs in developing countries, patient data privacy concerns, unstable payment models, and resistance from traditional healthcare providers are challenging the growth of this market to a certain extent. Market Dynamics 1. Increasing incidence of preventable chronic diseases 2. Risi...
Post a Comment
Read more

Health Information Exchange (HIE) Market Worth USD 2.0 Billion By 2025 : Growing Adoption Of EHRs

  What This Report Will Provide?  This study involved four major activities in estimating the size of the health information exchange market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. Expected Revenue Growth: [199 Pages Report]  The  global health information exchange market  is expected to reach USD 2.0 billion by 2025 from USD 1.1 billion in 2020, at a CAGR of 12.2%. Major Growth Boosters: Growth in this market can be attributed to factors such as growing need to curtail healthcare costs, focus on patient-centric care delivery, growing adoption of EHRs and other HCIT solutions, government initiatives for enhancing patient care and safety, government funding for healthcare interoperabilit...
Post a Comment
Read more